EQT and Sanofi Ventures led a $97m Series B round in Atalanta Therapeutics.

EQT and Sanofi Ventures led a $97m Series B round in Atalanta Therapeutics, a biopharmaceutical company, with participation from RiverVest Venture Partners, Novartis Venture Fund, abrdn, Pictet Alternative Advisors, Mirae Asset Financial, GHR Foundation and F- Prime Capital. “This financing validates the truly transformative potential of Atalanta’s best- in-class di-siRNA platform for delivering oligonucleotide therapies to the central nervous system and the exciting promise of our expansive wholly- owned pipeline. Importantly, this Series B will support a path to the clinic for two programs for serious neurological diseases that today lack disease-modifying therapies — KCNT1-related epilepsy and Huntington’s disease — and will anchor our growing franchise of investigational medicines for Huntington’s disease. We are diligently progressing these programs toward IND submissions next year so that we can start our Phase 1 trials and reach patients who are waiting," Alicia Secor, Atalanta President and CEO.